

Review Article

Stem Cell in Regenerative Medicine and Personalized Therapeutics

Shiva Verma^{1*}, Gopal Jee Tiwari², Saral Shukla³, Shraddha Singh⁴, Shanmugapriyan Veeranan⁵

¹ School of Health Sciences and Technology, Indian Institute of Technology Guwahati, Assam, India.

² Assistant Professor, Department of Biotechnology, Goel Institute of Technology & Management Lucknow U.P. India.

³ Department of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.

⁴ Department of Zoology, University of Allahabad, Prayagraj, Uttar Pradesh, India.

⁵ Department of Plant Biotechnology, Tamil Nadu Agricultural University, Tamil Nadu, India.

ORCID:  [SV 0009-0008-3445-287X](https://orcid.org/0009-0008-3445-287X)^{1*},  [GJT 0009-0003-2591-7237](https://orcid.org/0009-0003-2591-7237)²

 [SS 0009-0006-1479-2469](https://orcid.org/0009-0006-1479-2469)³,  [SS 0009-0007-2870-8309](https://orcid.org/0009-0007-2870-8309)⁴

 [SV 0009-0002-4404-1827](https://orcid.org/0009-0002-4404-1827)⁵

Correspondence should be addressed to Shiva Verma: sv4383411@gmail.com

Article No: 003 | **Accepted:** 06 September 2026 | **Published:** 10 October 2026

Abstract: Stem cells in regenerative medicine have become key players, strong potential for tissue or organ repair, replace and regenerate, disease modelling, and new therapeutics approach. Ability to self-renew and differentiate into multiple desired cell lineages, making it more valuable for treating wide range of diseases including cardiovascular diseases, osteoarthritis disorder, neurodegenerative disorders and also in cancer. Recent research and innovation progress in pluripotent stem cells technologies, special induced pluripotent stem cells (iPSCs). have enabled therapeutics in new era of medicines. Inclusion of stem cell research with personalized medicine is supporting development of precise targeted and effective treatments with lesser side effects. Advanced technique and innovation like organoids, 3D bioprinting, disease model and organ-on-chip systems, along with biomaterial enhancement, scaffold and extracellular vesicles, improving application of the stem cells in both research and innovation as well as clinical application. Technologies provide more realistic human tissue models and improve prediction of treatment outcomes via disease models which one directly supports clinical trials. Rather than these advancements, lots of challenges remain, including standard compliance and regulatory limitations. Critical examination of translational barriers and future directions necessary to realise full clinical potential of stem cell technologies, in regenerative medicine and personalized therapeutics. Very essential to continue this interdisciplinary research and innovation with advancing safety, effectiveness and patient-specific regenerative therapies.

Keywords: Stem Cells, Regenerative medicines, Personalized Therapeutics, Precision Therapy, Induced Pluripotent Stem Cells (iPSCs), Organoids, Organ-on-Chip, Tissue Engineering, Precision Medicine, Biomaterials, 3D Bioprinting, Cell Therapy, Extracellular Vesicles.

1. Introduction

Stem cells are emerging in modern biomedical science and new era of medicine, due to their unique potential for self-renewal and differentiation into diverse cell lineages, transformative potential for regenerative medicine and disease modelling [1,18]. The foundational discovery of human embryonic stem cells and development of induced pluripotent stem cell (iPSCs) has significantly expanded scope of patient-specific therapeutic strategies, enabling reprogramming of somatic cells into pluripotent states [18-20]. Advances have positioned stem cell based approaches at next-generation therapeutics, bridging conventional fundamental biology to modern personalized biology with clinical research and innovation [1,24].

Regenerative medicine integrating stem cell biology, biomaterials, personalized therapeutics and tissue engineering to restore or replace as well as regenerate damaged tissues and organs [3,11]. Mesenchymal stromal cells (MSCs) and other adult stem cell populations have promising outcomes in musculoskeletal, immunological disorders, and cardiovascular, though related challenges exist like safety, scalability, and long-term efficacy persist [9,35]. Therapeutic topography is next enriched by extracellular vesicles and paracrine signalling mechanisms, which is increasingly recognized for its role in mediating regenerative effects without direct cell transplantation at sites [14,59]. The paradigm of personalized and precision medicine is reshaping healthcare via personalised treatments based on individual genetic molecular, biological and environmental profiles [5,17]. The stem cell technologies with targeted therapies, thus enhancing therapeutic efficacy while minimizing side effects [10,2]. This integration is evident in use of iPSCs for disease modelling, drug screening, organ-on-chip and identification of individualised treatment routine [6,24]. Emerging tools and technologies like organoids and organ-on-chip systems are revolutionising translational clinical research by providing physiobiologically relevant models which closely mimic human tissue function and architecture [7,8,54]. Organoids derived from stem cells enable the study of complex developmental cellular development, drug cell response analysis and disease mechanisms, other side microfluidic organ-on-chip techniques helping real-time analysis of cellular response under controlled condition [7,8]. Additionally, advancement in 3D bioprinting and biomaterial engineering is enabling fabrication of functional tissue constructs, accelerating translation of laboratory findings into clinical applications and advantages [11,12]. The significant translational gap remains between experimental success and clinical implementation. Factors like tumorigenicity risks, immunogenicity, regulatory and manufacturing complexities continue to limit widespread adoption of stem cell-based therapies but scientists and researchers soon overcome [34,38]. Addressing and overcoming limitations requires interdisciplinary

collaboration, regulatory structure and integration of advanced computational, tissue engineering and bioengineering tools [2]. The evolving synergy between stem cell biology, regenerative medicine and personalized therapeutics represents standard shift in modern healthcare. By leveraging cutting-edge technologies, we overcome translational challenges. This field holds huge promise of delivering precise, effective and patient-specific therapeutics and medication in the near future [25].

2. Types and Biological Characteristics of Stem Cells

2.1 Embryonic Stem Cells (ESCs)-

Origin: Embryonic stem cell is derived from inner cell mass (ICM) of blastocyst early-stage preimplantation embryo formed within 3-5 days of post-fertilization [60].

Biological Traits: ESC is pluripotent cells with ability to differentiate in specialized cell lineage as per niche, derivatives of all three germ layers-ectoderm, mesoderm, and endoderm-giving rise to virtually all specialized cell types in the body. They sustained self-renewal capacity under appropriate in vitro culture conditions such as microenvironment [1,18,60].

2.2 Adult Stem Cells (ASCs)-

Origin: Adult stem cell (ASCs) is undifferentiated cells residing within specialized microenvironments, known as stem cell “niches”, in fully developed tissues like bone marrow, skin, brain, and muscle. The niches play crucial role in regulating stem cell maintenance, differentiation and activation [61].

Biological Traits: Adult stem cell is multipotent, processing capacity to differentiate into limited range of cell types specific to tissue origin, like hematopoietic stem cells (HSCs) give rise in blood cell lineages, though neural stem cells generate neurons[1,19,61].

Key Feature: Adult stem cell primary function is to maintain tissue homeostasis by continuously replacing damaged and facilitating tissue repair throughout lifetime of organism. This regenerative capability undergoes therapeutic potential in treating degenerative diseases; dysregulation of proliferative control mechanisms may contribute to tumorigenesis or carcinogenesis [15,61].

2.3 Mesenchymal Stem Cells (MSCs)

Origin: Mesenchymal stem cell are primarily isolated from multiple adult and perinatal tissue, including bone marrow, adipose tissue, umbilical cord blood, dental pulp, and placental tissue [2]. Their presence across diverse tissue source highlight their physiological role in tissue maintenance and repair [69].

Biological Trait: MSC represent a specialized subset of adult stem cell characterised via their multipotent differentiation capacity. They can rise to stromal lineages such as osteoblast (bone forming cell), chondrocyte (cartilage forming cell) and adipocyte (fat cell). They also express distinct set of surface marker (like CD73, CD90, CD105) while

lacking in hematopoietic marker, which are critical for their identification and isolation [61,69].

Key Feature: Feature of MSCs is their potent immunomodulatory capability. They secrete broad spectrum of bioactive molecule, including cytokine, chemokine, growth factor and extracellular vesicle, which collectively regulate immune responses and modulate the inflammatory microenvironment (Niche). Through interaction with immune cell such as T lymphocyte, B cell, macrophage, and dendritic cells, MSC suppress excessive immune activation and promote tissue regeneration. This property make them highly promising candidate for treatment of autoimmune disorder, inflammatory disease, and fibrosis-related tissue damage [69].

2.4 Induced Pluripotent Stem Cells (iPSCs)

Origin: Induced pluripotent stem cell are artificially generated by reprogramming of somatic (fully differentiated) cell- such as fibroblast from skin or peripheral blood cell- into pluripotent state. This process is achieved by introducing defined set of transcription factor, classically known as the Yamanaka factors (OCT3/4, SOX2, KLF4 and c-Myc). Which reset the epigenetic and transcriptional landscape of cell to an embryonic like state [1,24].

Biological Traits: iPSC exhibits similar properties of pluripotency including unlimited self-renewal and ability to differentiate into derivative of all three germ layers (ectoderm, mesoderm and endoderm). At molecular level, they closely resemble embryonic stem cell (ESC) in term of gene expression profile, epigenetic signature, and differentiation potential. However, their generation involve extensive cellular reprogramming, which may introduce genetic and epigenetic variability necessitating careful screening for genomic stability and tumorigenic risk prior to clinical application. But after careful screening of genomic stability Japan approved regenerative medicine [1,24].

Key Feature: Advantage of iPSCs lies in their ability to avoid ethical concerns associated with use of embryonic stem cell, as they do not destroy human embryos. iPSC as powerful platform for personalized regenerative medicine, disease modelling and drug screening, although challenges such as tumorigenicity, immunogenic variability and scalability remain critical consideration for their clinical translation [1,24].

3. Biological Basis of Stem Cells

3.1 Self-Renewal and Differentiation Mechanisms The core of stem cell biology lies in principle of asymmetry division, where a stem cell divides to generate an identical daughter cell (maintaining stem cell loop) and a progenitor cell committed to differentiation cell line [32,38] (Fig 3.1).

Self-renewal is tightly regulated by intrinsic genetic programs and extrinsic signaling pathways that preventing premature senescence or differentiation, ensuring sustained loop of undifferentiated cells in whole life [38,47]. Stem cell self-renewal process is maintained by intrinsic transcription factors such as Oct4, Sox2 and Nanog. These factors are responsible for maintaining pluripotency and preventing differentiation. Extrinsic

signaling pathways such as LIF/STAT, Wnt, and BMP promote proliferation of stem cells and inhibit lineage commitment [104]. While analyzing the epigenetic mechanisms, pluripotency is preserved by DNA hypomethylation of the Oct4 promoter, maintenance of methylation patterns by DNA methyltransferases (Dnmt3a/Dnmt3b) activity and repression of stem cells differentiation genes by Polycomb repressive complexes (PRC1/PRC2). Also, chromatin remodeling factors regulate the accessibility of stemness genes [103].

Differentiation is primarily governed through epigenetic modifications such as DNA methylation and histone protein modification, which one regulates activating or silencing lineage-specific genes [46,]. This process result in acquisition of the specialized structural and functional characteristics of cell such as neuron, myocyte, or epithelial cell [47]. Differentiation process is triggered by downregulation of Oct4, Sox2 and Nanog transcription factors along with activation of lineage specific pathways like FGF/TGF- α and BMP (in human embryonic stem cells) signaling [104]. This change occurs because of epigenetic modifications such as de novo DNA methylation, H3 and H4 acetylation and loss of polycomb mediated repression. Thus leads to the activation of developmental regulators. Additionally, p53-mediated suppression of Nanog factors promotes lineage commitment and elimination of damaged pluripotent cells [103].




Figure 3.1: Overview of stem cell lineage, biological functions, reprogramming strategies and their applications in regenerative medicine. This illustration represents the major stem cell types and their differentiation into different specialized lineages such as neural, cardiac, muscle and blood cells. It highlights the key properties such as self renewal

& differentiation of stem cells, paracrine signalling and immune response modulation. Somatic cell reprogramming into induced pluripotent stem cells (iPSCs) by Yamanaka factors are illustrated in the stem cell therapy portion. The bottom right section highlights the diverse clinical application of stem cells in regenerative medicine.

3.2 Stem Cell Niche and Microenvironment: Stem Cells have a specialized microenvironment known as **stem cell niche**, which regulates fate decisions including quiescence, self-renewal and differentiation [1,32].

- **Physical Factors:** such as extracellular matrix stiffness and mechanical forces like stress from neighboring cells in tissue or organ, provide biomechanical hints to influence stem cell behavior [11].
- **Chemical Signals:** within niche/microenvironment includes cytokines, metabolic conditions and transcriptional factors [108]. Like hematopoietic stem cells in bone marrow is maintained in hypoxic environment that minimize oxidative stress and preserves stemness [15,107].
- **Cell-to-Cell Contacts:** are equally critical, where adhesion molecules and direct contact with stromal or support cells maintain stem cell identity and prevent premature differentiation [32,47].

3.3 Pluripotency and Reprogramming-

- **Pluripotency:** is ability of stem cells to differentiate into all cell types of body and maintained by core transcriptional factors including **Oct4, Sox2, and Nanog** [1,24]. Transcription factors sustain open chromatin state and prevent lineage commitment [24,105].
- **Reprogramming:** involves transformation of somatic cells into induced pluripotent stem cells (iPSCs) by introduction of defined transcription factors, known as **Yamanaka factors** [1,19,24]. This process resets epigenetic landscape and restores pluripotency of somatic cells, enabling generation of patient-specific stem cells for research and therapy [6,37,106].

4. Stem Cells in Regenerative Medicine

4.1 Tissue Repair and Regenerative Mechanisms- Stem cells contribute to tissue repair by multiple mechanisms beyond direct differentiation.

- **Differentiation:** enables replacement of damaged or dead cells such cardiomyocytes [35].
- **Paracrine Signalling:** play a crucial role, where stem cells secrete growth factors, cytokines, and extracellular vesicles that modulate inflammation, enhance tissue repair, replacement, regeneration and activate endogenous stem cells [2,14].
- **Angiogenesis:** is stimulated by stem cell-secreted related factors, promoting formation of new blood vessels and improving oxygen and nutrients delivery to injured tissues [15]. These combined mechanisms highlight multifaceted therapeutic potential of the stem cells in regenerative medicines [3,13].

4.2 Applications in Major Diseases

4.2.1 Cardiovascular Diseases Cardiac tissue exhibit limited regenerative capacity; so stem cell-based therapies aim to restore function following injury [35].

- **Repair Infected Tissue:** by replacing scarred tissue with functional cardiomyocytes [6,42].
- **Improve cardiac contractility:** and overall heart function in heart failure patient [42].

4.2.2 Neurodegenerative Disorders- Neurodegenerative diseases, including Parkinson's and Alzheimer's are characterized by progressive neuron loss.

- **Dopamine Restoration:** strategies involve differentiating stem cell into dopaminergic neurons to treat Parkinson's disease [15,48].
- **Neuroprotection:** is achieved via secretion of neurotrophic factors which support neuronal survival and reduce neuro-degeneration [15].

4.2.3 Musculoskeletal Disorders- Mesenchymal stem cells (MSCs) are widely used in orthopedic therapies as regenerative medicine [2].

- **Cartilage Repair** applied in the osteoarthritis to regenerate articular cartilage for normal function [9,40].
- **Bone healing and regeneration** enhancing healing in fractured and spinal injuries via regeneration properties of stem cells [9, 50].

4.2.4 Diabetes and endocrine disorders- Stem cell therapies offers promising strategies for restoring insulin regulation in patients.

- **Islet Cell Replacement** using iPSC-derived beta cells of pancreas aims to restore insulin production in Type-I diabetes patients [34].
- **Immune Modulation** helps to reduce autoimmune destruction of pancreatic cells or reduce autograft rejection of transplants [15].

4.2.5 Cancer and Oncology- Stem cells serving both therapeutic and functional roles in oncology to delete cancers..

- **Bone Marrow Transplants:** A well-established therapy for hematological malignancies like leukemia treatment via bone marrow transplants [13, 48].
- **Targeted Drug Delivery:** uses of engineered stem cells as carrier of drug candidates to deliver anticancer agents at targeted tumor sites, minimizing systemic toxicity like ADMET studies or new studies have to perform for engineered stem cells carrier drug delivery [48].

5. Stem Cells in Personalized Therapeutics

Personalized therapeutics is rapidly evolving through the integration of stem cell technologies, particularly with the advent of induced pluripotent stem cells (iPSCs), which enable patient specific disease modeling, drug screening, and regenerative therapies [70]. The concept of precision medicine tailoring medical treatment to individual genetic,

environmental, and lifestyle factors has been significantly advanced by stem cell research, especially through the use of patient-derived iPSCs that can recapitulate unique disease phenotypes and predict drug responses. Pharmacogenomics further enhances this approach by leveraging genetic information to optimize drug efficacy and minimize adverse effects, often using iPSC based platforms for preclinical testing [70,71].

5.1 Concept of Precision Medicine

Precision medicine refers to customizing healthcare including prevention, diagnosis, and treatment based on individual variability in genes, environment, and lifestyle. It moves beyond a “one-size-fits-all” approach by integrating genomic data with clinical information to guide therapeutic decisions[71,72]. In regenerative medicine and cellular therapy, precision medicine leverages patient-specific data to optimize outcomes from interventions such as stem cell transplantation or gene editing. Precision medicine is a transformative healthcare model that moves away from the "average patient" prototype. In the context of regenerative medicine, it represents the shift from allogeneic (donor-matched) to autologous (self-derived) logic [72,73].

5.1.1 The core of precision medicine: The core lies in the "OMICS" integration genomics, transcriptomics, proteomics, and metabolomics. By analyzing these layers, clinicians can predict a patient's susceptibility to specific diseases and their likely response to stem cell-based interventions[73].

5.1.2 The Goal: It aims to ensure that the regenerative triggers (like growth factors or stem cell transplants) are synchronized with the patient's unique microenvironment (the "niche"), thereby reducing the risk of immune rejection and increasing therapeutic efficacy[74].

5.2 Patient Derived iPSCs

Induced pluripotent stem cells (iPSCs) are somatic cells reprogrammed back into a pluripotent state capable of differentiating into any cell type. Patient-derived iPSCs retain the donor's genetic background, enabling disease modeling that reflects individual pathophysiology. Patient-derived iPSCs are the cornerstone of personalized therapeutics [73,74]. By taking a simple skin or blood sample and "reprogramming" it using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), we create cells that are genetically identical to the patient. The true power of iPSCs is "Disease Modeling in a Dish." For example, if a patient has a rare cardiac arrhythmia, their iPSCs can be differentiated into beating cardiomyocytes [75,76]. These cells will exhibit the same electrical malfunctions as the patient's heart. These models are used for studying rare diseases, predicting drug responses, developing autologous cell therapies with reduced risk of immune rejection, and generating organoids for complex tissue modeling. Advances include non-invasive sources (e.g., urine derived iPSCs) and integration with gene-editing technologies like CRISPR/Cas9 for correcting pathogenic mutations [75,76,77] (Fig 5.1).




Figure 5.1: Integrated Pipeline for Patient-Derived iPSC Modeling and Gene Therapy.

Graphical representation of the workflow starting from somatic cell collection (skin fibroblasts or non-invasive urine-derived cells) to the generation of patient specific iPSCs through Yamanaka factors such as Oct4, Sox2, Klf4, c-Myc. The workflow highlights the integration of CRISPR/Cas9 tool for correcting the pathogenic mutations followed by in vitro differentiation into multiple lineages like cardiomyocytes, hematopoietic, islet of langerhans, and neural cells. These organoids serve as platforms for “Disease Modeling in a Dish” and drug screening applications. Also, it is useful in autologous transplantation with minimal risk of immune rejection.

5.3 Pharmacogenomics and Cell-Based Therapy

Pharmacogenomics studies how genetic variation affects drug response. When combined with iPSC technology, it enables high-throughput drug screening on patient specific cells to predict efficacy/toxicity before clinical use [77]. This approach supports the development of safer drugs tailored to individual patient’s genetic profiles, facilitates discovery of new therapeutic targets, and helps prevent adverse drug reactions by modeling them in vitro using iPSC derived tissues [78,79,80].

Dimension	Conventional Therapy	Personalized Stem cell Therapeutics
Cell Source	Allogeneic (donor-derived)	Autologous (Patient-derived)
Immune Strategy	Requires Immunosuppression	Reduced immune rejection and improved immunocompatibility
Genetic Consideration	Generalized population-based approach	Customized based on individual genetic profile (e.g., SNPs)
Model Fidelity	Animal models and generic cell lines	Patient-specific models(“disease-in-a-dish”)
Therapeutic objective	Symptom management	Targeted regeneration and disease correction
Drug Development	Empirical, trial and error approach	Patient specific drug screening and response prediction
Clinical Translation	Widely used in clinical practice	Emerging/under clinical evaluation
Safety Profile	Higher risk of immune rejection	Improved safety due to patient specificity

Table 5.1: Comparative analysis of Conventional Therapy versus Personalized Stem Cell Therapeutics. This table explains the most basic and important shifts in regenerative medicine. Unlike conventional allogeneic treatments, which require immunosuppression and rely on animal models, personalized iPSC based therapies make use of autologous sources to ensure the minimal risk of immune rejection. By focusing on individual genetic markers like Single Nucleotide Polymorphisms (SNPs) and high-fidelity "Disease in a Dish" models, this strategy aims for molecular level regeneration rather than symptom management.

6. Advanced Technologies Enhancing Stem Cell Applications

6.1 Organoids Organoids are three-dimensional (3D) miniature structures cultured in vitro produced from either human pluripotent stem cells (hPSCs) or adult stem cells (AdSCs) derived from healthy individuals or patients that recapitulate the cellular heterogeneity, structure, and functions of human organs. The advent of human 3D organoid systems is now possible to allow remarkably detailed observation of stem cell morphogens, maintenance and differentiation resemble primary tissues, enhancing the potential to study both human physiology and developmental stage. As they are similar to their original organs and carry human genetic information, organoids derived from patient hold great promise for biomedical research and preclinical drug testing and is currently used for personalized, regenerative medicine, gene repair and transplantation therapy [100].

6.2 Organ on Chip Systems-Organ-on-chip systems are versatile tools that can be used to recreate complex tissues in vitro to study human physiology and guide drug

development. The key to creating representative ex vivo models is to incorporate relevant cell populations that mimic physiological structures in emulated tissue microenvironments. Commonly used fabrication techniques (such as lithography and gel confinement) for the development of organ-on-chip systems have a limited capacity to create tissue structures with complex three-dimensional (3D) organization [101].

6.3 3D Bioprinting- Three-dimensional (3D) bioprinting, an additive manufacturing based technique of biomaterials fabrication, is an innovative and auspicious strategy in medical and pharmaceutical fields. The ability of producing regenerative tissues and organs has made this technology a pioneer to the creation of artificial multi-cellular tissues/organs. A broad variety of biomaterials is currently being utilized in 3D bioprinting as well as multiple techniques employed by researchers.[102]

6.4 Biomaterials and Scaffolds- A scaffold serves as a structural template for cell attachment and tissue formation, and it is designed to define the shape, size, and structural properties of the forming tissues. The scaffold is also an informational template, by virtue of its mechanical properties, immobilized and released bioactive factors and cell receptor ligands, and overall architecture (including surface properties, pore size and connectiveness, orientation, and alignment). To mimic the anisotropy of native tissues (such as bone or heart), scaffolds are also made of materials that have different structural and mechanical properties in different directions (Peppas and Langer, 1994; Hubbell 1995; Langer and Tirrell, 2004).[101]

6.5 Extracellular Vesicles and Exosomes

6.6 Nanotechnology in Stem Cell Therapy Currently, stem cell nanotechnology is one of the novel and exciting fields. Certain experimental studies conducted on the interaction of stem cells with nanostructures or nanomaterials have made significant progress. The significance of nanostructures, nanotechnology, and nanomaterials in the development of stem cell-based therapies for degenerative diseases and injuries has been well established. Specifically, the structure and properties of nanomaterials affecting the propagation and differentiation of stem cells have become a new interdisciplinary frontier in material science and regeneration medicines [85,86].

7. Clinical Translation and Current Trials

7.1 Overview of Clinical Trials

The clinical translation of stem cell therapies is steadily progressing, although it still requires careful evaluation. A large number of clinical trials have been registered, mainly using mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) for treating cardiovascular, neurodegenerative, autoimmune, and orthopedic disorders. Early phase trials are primarily focused on safety, whereas later stages evaluate the effectiveness of these therapies [64]. However, many studies report modest or inconsistent outcomes, which reflects the complexity of biological systems. In practical terms, only a limited number of therapies have shown clear clinical benefits. For example, hematopoietic (bone marrow) stem cell transplantation remains the gold standard treatment for several blood cancers [64].

7.2 Success Stories and Approved Therapies

In case you seek a definite success, consider transplants of hematopoietic stem cells. Doctors have placed their trust in them for many years to care for leukemia, lymphoma, as well as other blood cancers. Once patients receive high dose chemotherapy, these transplantations basically regenerate the circulatory and immune systems. That is a significant, tangible success for stem cell treatment [65]. More recently, regenerative medical science has developed via innovative cell-based treatments. Use mesenchymal stem cell (MSC) treatments to help manage immune system conditions such as graft versus host disease (GVHD). Remestemcel L (Ryoncil) represents a type of an MSC treatment approved for specific inflammatory conditions [67]. Additionally, stem cell-based approaches have been successfully applied in tissue repair and regeneration. Limbal stem cell therapy for corneal regeneration (e.g., Holoclar) has demonstrated clinical efficacy and received regulatory approval in Europe. Similarly, engineered skin substitutes derived from stem cells have shown promising outcomes in burn treatment and wound healing [66].

7.3 Challenges in Clinical Translation

Despite considerable progress, the translation of stem cell therapies from laboratory research to clinical application remains challenging. One of the key barriers is the so-called “translational gap,” where promising results observed in preclinical models fail to replicate in human patients. This discrepancy is largely due to the complexity of human biology and differences between experimental models and clinical conditions [68]. Several biological and technical factors contribute to this challenge. For instance, transplanted stem cells often show limited survival, poor engraftment, or inadequate functional integration into host tissues. In addition, delivery methods can influence therapeutic outcomes; intravenous administration may lead to cell trapping in non-target organs or trigger infusion-related complications [66]. Another major issue is the lack of consistency across studies. Variations in cell sources, culture conditions, expansion protocols, and dosing strategies can result in inconsistent and difficult-to-reproduce outcomes. This lack of standardization makes it challenging to compare results across clinical trials and slows the development of universally accepted treatment protocols [67]. Also in addition, regulatory and economic barriers also play a significant role. The approval process for stem cell therapies is complex and requires extensive safety and efficacy data. At the same time, the high cost of cell production, storage, and clinical application limits accessibility.

8. Challenges and Limitations

8.1 Tumorigenicity and Safety Concerns The link between stem and tumor cells in science is a very old one. The earliest research on highly pluripotent stem cells was conducted not on normal stem cells, but instead on embryonic carcinoma cells (EC) derived from teratocarcinoma. EC had unusual stem-like properties that attracted a great deal of attention at the time, including a surprising degree of plasticity. Teratocarcinoma and its benign cousin teratoma are the best examples of tumors with substantial populations of pluripotent stem cells as well as differentiated tissues [104].

Stem cells hold promise in regenerative medicine due to their ability to proliferate and differentiate into various cell types. However, their self-renewal and multipotency also raise concerns about their tumorigenicity during and post-therapy. Indeed, multiple studies have reported the presence of stem cell-derived tumors in animal models and clinical administrations. Therefore, the assessment of tumorigenicity is crucial in evaluating the safety of stem cell-derived therapeutic products. Ideally, the assessment needs to be performed rapidly, sensitively, cost-effectively, and scalable [62,63].

8.2 Immune Rejection and Compatibility One of the major goals of regenerative medicine is repair or replacement of diseased and damaged tissues by transfer of differentiated stem cells or stem cell-derived tissues. The possibility that these tissues will be destroyed by immunological rejection remains a challenge that can only be overcome through a better understanding of the nature and expression of potentially immunogenic molecules associated with cell replacement therapy and the mechanisms and pathways resulting in their immunologic rejection. Stem cells and their differentiated progeny offer great hope for treating disease by providing an unlimited source of cells for repairing or replacing damaged tissue. Initial studies suggested that, unlike 'normal' transplants, specific characteristics of stem cells enabled them to avoid immune attack. However, recent findings have revealed that the immunogenicity of stem cells may have been underestimated. [87,88]

8.3 Ethical and Regulatory The possibility of modifying disease through regenerative medicine applications, particularly stem cell therapies, raises ethical and regulatory challenges in medical fields. The most important ethical issues in stem cell research and therapy, the clinical use in regenerative and transplantation medicine. The ethical challenges regarding human embryonic stem cell (hESC) research, therapeutic potential and clinical translation of induced pluripotent stem cell (iPSC) and safety issues of mesenchymal stem cell (MSC)-based therapy [89,90].

8.4 Manufacturing and Cost Constraints Manufacturing is the critical challenge that limits the translation of a regenerative medicine technology into a commercial product. To identify the problem we will survey the current regenerative medicine manufacturing landscape by taking a look at the major manufacturing challenges that regenerative medicine technologies face and what manufacturing solutions can overcome these challenges and greatly accelerate process development [91].

8.5 Reproducibility and Standardization Advancing the use of human stem cell-based models on preclinical and regulatory testing fields requires the performance of rigorous and reproducible research. Quality standards and reporting best practices should be promoted to ensure the reliability and translatability of stem cell models and results. Strategies to increase awareness and implementation of best practices and standards will require training initiatives and collaboration across relevant stakeholders. Overall, improving the quality and reproducibility of stem cell-based models and methods through best practices and standards will accelerate their adoption in industrial and regulatory

contexts and ultimately drive the development of effective therapies and safer chemicals [92].

9. Future Perspectives

The landscape of regenerative medicine is undergoing a paradigm shift, moving beyond standardized treatments toward a highly integrated and technologically driven ecosystem [23,99]. The convergence of computational power, precise genomic tools, and advanced bioengineering is addressing long-standing challenges in scalability and reproducibility [99]. This section explores the emerging frontiers ranging from artificial intelligence to organ on a chip systems that are collectively steering the field toward the ultimate goal of precision regenerative medicine [23] (Fig 9.1).

9.1 Integration with AI and Machine Learning

The integration of artificial intelligence (AI) and machine learning (ML) into stem cell research is expected to play a transformative role in the coming years [95]. Traditional stem cell experiments often involve trial and error approaches, which are time consuming and sometimes inconsistent [95]. In contrast, AI driven systems can analyze large datasets, including imaging data, gene expression profiles, and cellular behavior, to identify patterns that may not be easily recognized by researchers [94,95]. For example, machine learning models are now being used to monitor stem cell differentiation in real time, allowing researchers to predict cell fate and optimize culture conditions accordingly [80]. This not only improves efficiency but also reduces variability between experiments, which has long been a challenge in regenerative medicine [80,94]. In addition AI has the potential to standardize protocols across laboratories by identifying the most effective conditions for cell growth and differentiation [95]. As these technologies continue to evolve, they are likely to accelerate drug discovery, improve quality control in stem cell production, and ultimately make regenerative therapies more reliable and scalable [80].

9.2 Gene Editing and CRISPR-Based Approaches

Gene editing technologies, particularly CRISPR/Cas9, have introduced a new level of precision in regenerative medicine [96,97]. One of the most promising applications is the correction of disease causing mutations in patient derived stem cells before transplantation[96]. This approach is especially relevant for genetic disorders, where treating the root cause of the disease can lead to long term or even permanent solutions [96]. For example, recent clinical advancements have demonstrated the successful use of CRISPR edited hematopoietic stem cells in treating conditions such as sickle cell disease and β thalassemia [81]. In these cases, the patient's own cells are modified to correct the defective gene and then reintroduced into the body, significantly improving clinical outcomes [81]. Despite these advances, challenges remain, including off target effects, delivery efficiency, and long-term safety [97]. However, continuous improvements in gene editing techniques and delivery systems are expected to address these limitations, making CRISPR based stem cell therapies a cornerstone of future personalized medicine [96,97].

9.3 Next-Generation Stem Cell Therapies

The next generation of stem cell therapies is moving beyond simple cell transplantation toward more complex and functional tissue engineering approaches [98]. One of the most exciting developments in this area is the use of organoids three dimensional structures derived from stem cells that mimic the architecture and function of real organs [82,27]. These mini organs have already been used extensively for disease modeling and drug testing, and they hold great potential for future transplantation therapies [82]. The next generation of stem cell therapies is moving beyond simple cell transplantation toward more complex and functional tissue engineering approaches [98]. One of the most exciting developments in this area is the use of organoid three dimensional structures derived from stem cells that mimic the architecture and function of real organs [82,27]. These mini organs have already been used extensively for disease modeling and drug testing, and they hold great potential for future transplantation therapies [82].

9.4 Personalized Regenerative Platforms

The future of regenerative medicine is increasingly shifting toward personalized treatment strategies [23,99]. Instead of using a one size fits all approach, therapies are being designed based on an individual's genetic and cellular profile [23]. Patient derived induced pluripotent stem cells (iPSCs) play a central role in this transition, as they allow the generation of patient specific tissues for both therapeutic and research purposes [99]. Technologies such as organ on chip systems further enhance this approach by enabling the simulation of human organ functions in a controlled environment. These systems can be used to test drug responses on patient specific cells, providing valuable insights into treatment effectiveness and potential side effects before clinical application [98]. In addition, the integration of computational modeling with biological data allows for more accurate prediction of treatment outcomes [23]. This combination of stem cell technology, bioengineering, and data science is expected to lead to highly tailored therapies that improve efficacy while minimizing risks. Overall, personalized regenerative platforms represent a major step toward precision medicine, where treatments are customized to meet the unique needs of each patient [99].

FUTURE PERSPECTIVES: AN INTEGRATED ECOSYSTEM FOR ADVANCED STEM CELL THERAPIES




Figure 9.1: Conceptual Framework for an Integrated Ecosystem in Advanced Stem Cell Therapies. The schematic diagram highlights the interaction between four key technological pillars which defines the future of regenerative medicine. On the left side of illustration, AI and ML analyze multi-omics and imaging data to predict the cells fate and optimize protocols, while Gene Editing corrects defective mutations. Both technologies connect to the central biological core, where the patient specific induced pluripotent stem cells (iPSCs) retain the genetic background of the donor. Diagrammatic flow explains how the corrected iPSCs used in advanced modelling platforms like organoids that mimic real organ architecture and Organ-on-a-Chip simulate organ level functions. A critical feedback loop from Dish/Chip to AI/ML ensures continuous data processing for protocol optimization. The final point on the right is the Ultimate Goal: Precision Regenerative Medicine, which integrates these platforms to deliver highly personalized therapies to patients.

Discussion

In present review highlights the rapid evolution of stem cell biology from fundamental discoveries to clinical applications, Its central role in shaping regenerative medicine and personalised therapeutics. The discovery of pluripotent stem cells and recent development in induced pluripotent stem cells (iPSCs) have completely transformed the field by enabling patient-specific disease modelling like organ-on-chip and personalized therapeutic strategies [1,10-20]. These advancements have positioned stem cells not only as

tool for tissue regeneration but also as platforms for understanding disease mechanisms at molecular level [2,3].

While early expectation focused primarily on cell replacement, accumulating evidence suggests that therapeutic efficacy of stem cells, specially mesenchymal stromal cells (MSCs), is hugely mediated through secretion of bioactive factors, cytokines, and extracellular vesicle[13-15]. This paradigm shift toward cell-free regenerative strategies offer significant advantages in terms of safety, scalability, and regulatory as well as compliance, aligning with recent findings like regenerative medicine recently approved by Japan and other advancements in stem cell regenerative medicine and personalized therapeutics [14].

The integrated stem cell technologies and precision medicine represents another major advancement. Patient-derived iPSCs enabling recreation, replacement and regeneration of individual disease phenotypes in vitro, allowing high throughput drug screening and personalized therapeutic [5,17].

This approach is valuable in complex and heterogeneous diseases such as cardiovascular, neurodegenerative disorders and minimizing adverse effects [5,10].

Emerging technological innovations such as organoids, organ-on-chip systems and 3D bioprinting are significantly enhancing translational potential of stem cell research in regenerative medicine and personalized therapeutics [11,12].

The translation of stem cell therapies in routine clinical practice has several critical challenges but scientists and researchers overcoming these challenges like Japan has world-first approvals for iPSC-based therapies. Tumorigenicity remains major safety concern, due to high proliferative capacity and uncontrolled differentiation [1,21]. Regulatory compliance and manufacturing challenges also represent major barriers to clinical translation. The production of clinical-grade stem cells requires quality control, scalability, and cost-effectiveness but achievable with current technologies and emerging advancements in technologies [3]. Rather than ethical concerns, associated with embryonic stem cell, influencing public perception and regulatory policies [4]. These issues require establishment of regulatory and protocols to ensure safety, stability, efficacy, and reproducibility. The combination of artificial intelligence (AI) and machine learning (ML) is powerful tool for monitoring, optimizing stem cell culture, predicting differentiation outcome and reducing practical, experimental changes. Similarly, CRISPR/Cas9 gene-editing technologies in correcting genetic defects in personalized medicine [1]. Advances in technologies like patient-specific organoids and multi-organ-on-chip systems are overcoming gap by providing more accurate representations of stem cells and human biology[7,8].

In summary, review covers scientific advancements, innovation and future aspects, toward stem cell based therapies holding promises and personalized therapeutics. successful clinical translation, depends on challenges and limitations related to safety, stability, scalability and regulatory approval.

Conclusion

The Field of Stem Cell biology has undergone huge transformation, evolving foundational discoveries, dynamic and interdisciplinary domains like regenerative medicine, 3D bioprinting and personalized therapeutics. In review integrating key aspects of stem cell type, biological mechanisms, and emerging advancement. How these systems together contribute to tissue repair/replacement/regeneration, disease modelling, drug screening and next-generation personalized therapeutic strategies. Stem cells are not only serving as source of differentiated cell but also function as modulators of tissue microenvironment by paracrine signaling, immunomodulation, interaction with stem cell niche; has significantly enhanced therapeutic relevance across wide spectrum of diseases, including cardiovascular, neurodegenerative, musculoskeletal and metabolic disorder.

Integration of induced pluripotent stem cells with precision medicine represents major milestone toward personalized healthcare. Patient derived iPSCs enabling development of “disease-in-dish” model, facilitating accurate drug screening, toxicity, assessment and design of personalized medication strategies. Advancements in pharmacogenomics, gene editing, and biological computational tools, redefining how therapies are developed and delivered such as organoids, organ-on-chip system, 3D bioprinting, and advanced biomaterial have strengthening translational potential of stem cell research. These techniques and platforms provide relevant models bridging gap between in vitro experimentation and clinical application, improving predictability, efficiency, and scalability of regenerative therapies. Promising developments, significant challenges remain, issues related to tumorigenicity, immune compatibility, ethical consideration, manufacturing complexity and standardization limit widespread clinical adoption. Need to address and establish regulatory structural guidelines and standardized protocols to ensure safety, reproducibility and long-term efficacy.

Looking further, stem cell biology with gene editing technologies, artificial intelligence, and bioengineering as well as biomedical science is expected to accelerate the next level of innovation, research and overcome current limitations and challenges. The future of regenerative medicine and personalized therapeutics lie in integrated development, patient-specific therapeutic tools & techniques that are not only effective but scalable and accessible to all human beings.

Stem cell-based therapies are holding potential to move beyond conventional treatment toward tissue regeneration, replacement, repair and disease modification along with disease modelling. With continued scientific research and innovation, tools and technological advancement, ethical responsibility enhancement, this field has such a transformative potential in shaping the future of modern medicine.

Acknowledgement

The authors would like to acknowledge academic and research environment provided by their respective institution, which facilitated development of skill and work. The authors also extend their gratitude to colleagues, mentors, friends and family for

valuable insights and constructive discussions that contributed to refinement of this manuscript.

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding publication of this manuscript. All authors have approved final version and agree for submission.

Data availability of Statement

No new datasets were generated in preparation of this article. All information included in manuscript is derived from previously published studies which appropriately cited and given future aspects of advancement and current limitations.

Author contributions

All authors contributed to the study conception and design. Conceptualization, literature search, and initial drafting of the manuscript were performed by Shiva Verma. Manuscript structuring and critical revision were performed by Gopal Jee Tiwari. Data interpretation, literature curation, and technical validation were carried out by Saral Shukla. Editing and proofreading were conducted by Shraddha Singh. Visualization and generation of scientific figures and tables were performed by Shanmugapriyan Veeranan. All authors read and approved the final manuscript.

Supplementary Information

No supplementary information is associated with article.

References

1. Yamanaka S. Pluripotent stem cell-based cell therapy—promise and challenges. *Cell Stem Cell*. 2020 Oct 1;27(4):523–531. doi:10.1016/j.stem.2020.09.014.
2. Paliwal Swati, Chaudhuri Rituparna, Agrawal Anurag, Mohanty Sujata. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. *Journal of Biomedical Science*. 2018;25:31. doi:https://doi.org/10.1186/s12929-018-0429-1 .
3. Makarevich PI, Tkachuk VA. Fundamental and practical perspectives in regenerative medicine. *Int J Mol Sci*. 2024 Oct 26;25(21):11508. PMID: 39519061; PMCID: PMC11546304. doi: 10.3390/ijms252111508.
4. de Sá Silva F, Almeida PN, Rettore JVP, Maranduba CP, de Souza CM, de Souza GT, et al. Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy. *Scientifica (Cairo)*. 2012 Nov 20;2012:758102. PMID: 23226945; PMCID: PMC3514047. doi:10.1155/2012/758102.
5. Lightner AL, Chan T. Precision regenerative medicine. *Stem Cell Res Ther*. 2021;12:39. PMID: 33413590; PMCID: PMC7791634. doi: 10.1186/s13287-020-02092-w.
6. Ye L, Swingen C, Zhang J. Induced pluripotent stem cells and their potential for basic and clinical sciences. *Curr Cardiol Rev*. 2013;9(1):63–72. doi: 10.2174/157340313805076278.

7. Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, et al. Organoids: the current status and biomedical applications. *MedComm (2020)*. 2023;4(3):e274. PMID: 37215622; PMCID: PMC10192887. doi: 10.1002/mco2.274.
8. Singh D, Mathur A, Arora S, Roy S, Mahindroo N. Journey of organ on a chip technology and its role in future healthcare scenario. *Adv Pharmacol Sci Adv*. 2022 Apr 11;9:100246. PMCID: PMC9000345. doi:10.1016/j.apsadv.2022.100246.
9. Brown PT, Handorf AM, Jeon WB, Li WJ. Stem cell-based tissue engineering approaches for musculoskeletal regeneration. *Curr Pharm Des*. 2013;19(19):3429–3445. doi: 10.2174/13816128113199990350.
10. Naithani N, Sinha S, Misra P, Vasudevan B, Sahu R. Precision medicine: concept and tools. *Med J Armed Forces India*. 2021;77(Suppl 2):S303–S308. PMID: 34305276; PMCID: PMC8282508. doi: 10.1016/j.mjafi.2021.06.021.
11. Nugud A, Alghfeli L, Elmasry M, El-Serafi I, El-Serafi AT. Biomaterials as a vital frontier for stem cell-based tissue regeneration. *Front Cell Dev Biol*. 2022;10:713934. doi: 10.3389/fcell.2022.713934.
12. Tripathi S, Mandal SS, Bauri S, Maiti P. 3D bioprinting and its innovative approach for biomedical applications. *MedComm (2020)*. 2022;3(4):e194. PMID: 36582305; PMCID: PMC9790048. doi: 10.1002/mco2.194.
13. El-Kadiry AEH, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. *Front Med (Lausanne)*. 2021;8:756029. PMID: 34881261; PMCID: PMC8645794. doi: 10.3389/fmed.2021.756029.
14. Rafieezadeh D, Rafieezadeh A. Extracellular vesicles and their therapeutic applications: a review article (part 1). *Int J Physiol Pathophysiol Pharmacol*. 2024;16(1):1–9 doi:10.62347/QPAG5693.
15. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. *Signal Transduct Target Ther*. 2022;7(1):272. doi:10.1038/s41392-022-01134-4
16. Jain I, Chan AHP, Yang G, He H, Lam J, Sung K, et al. Combinatorial extracellular matrix tissue chips for optimizing mesenchymal stromal cell microenvironment and manufacturing. *npj Regen Med*. 2025;10:21. doi:10.1038/s41536-025-00408-z
17. Goetz LH, Schork NJ. Personalized medicine: Motivation, challenges and progress. *Fertil Steril*. 2018 Jun;109(6):952–963. doi: 10.1016/j.fertnstert.2018.05.006.
18. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. *Science*. 1998;282(5391):1145–1147. doi:10.1126/science.282.5391.1145
19. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007;131(5):861–872. doi:10.1016/j.cell.2007.11.019
20. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science*. 2007;318(5858):1917–1920. doi:10.1126/science.1151526
21. Daley GQ. The promise and perils of stem cell therapeutics. *Cell Stem Cell*. 2012;10(6):740–749. doi:10.1016/j.stem.2012.05.010
22. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. *Cell Stem Cell*. 2015;17(1):11–22. doi:10.1016/j.stem.2015.06.007
23. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med*. 2015;372(9):793–795. doi:10.1056/NEJMp1500523
24. Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. *Nat Rev Drug Discov*. 2017;16(2):115–130. doi:10.1038/nrd.2016.245
25. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. *Science*. 2008;322(5903):945–949. doi:10.1126/science.1162494
26. Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. *Nat Rev Mol Cell Biol*. 2016;17(3):194–200. doi:10.1038/nrm.2016.10

27. Clevers H. Modeling development and disease with organoids. *Cell*. 2016;165(7):1586–1597. doi:10.1016/j.cell.2016.05.082
28. Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic extracellular matrix materials. *Biomaterials*. 1999;20(1):45–53. doi:10.1016/s0142-9612(98)00107-0
29. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. *BMC Med*. 2011;9:52. doi:10.1186/1741-7015-9-52
30. Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies—bridging scientific observations and regulatory viewpoints. *Cytotherapy*. 2013;15(7):753–759. doi:10.1016/j.jcyt.2013.03.005
31. Shi Y, Despons C, Do JT, Hahm HS, Schöler HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. *Cell Stem Cell*. 2008;3(5):568–574. doi:10.1016/j.stem.2008.10.004
32. Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. *Cell*. 2008;132(4):598–611. doi:10.1016/j.cell.2008.01.038
33. Deinsberger J, Reisinger D, Weber B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. *NPJ Regen Med*. 2020;5:15. doi:10.1038/s41536-020-00100-4
34. Trounson A, Herbert M. Stem cell therapy for diabetes: what is needed to get there? *J Intern Med*. 2016;280(4):344–353. doi:10.4103/2230-8210.104045
35. Blau HM, Daley GQ. Stem cells in the treatment of disease. *N Engl J Med*. 2019;380(18):1748–1760. doi:10.1056/NEJMra1716145
36. Fernandez-Moure JS. Lost in translation: the gap in scientific advancements and clinical application. *Front Bioeng Biotechnol*. 2016;4:43. doi:10.3389/fbioe.2016.00043
37. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. *Nature*. 2012;481(7381):295–305. doi:10.1038/nature10761
38. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. *Stem Cell Res Ther*. 2019;10(1):68. doi:10.1186/s13287-019-1165-5
39. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. *Cell Stem Cell*. 2018;22(6):824–833. doi:10.1016/j.stem.2018.05.004
40. Toh WS, Brittberg M, Farr J, Foldager CB, Gomoll AH, Hui JHP, Richardson JB, Roberts S, Spector M. Cellular senescence in aging and osteoarthritis. *Acta Orthop*. 2016;87(sup363):6–14. doi:10.1080/17453674.2016.1235087
41. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. *Science*. 2013;340(6137):1190–1194. doi:10.1126/science.1234852
42. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. *Cochrane Database Syst Rev*. 2016;12(12):CD007888. doi:10.1002/14651858.CD007888.pub3
43. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. *PLoS One*. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559
44. Kimbrel EA, Lanza R. Next-generation stem cells—ushering in a new era of cell-based therapies. *Nat Rev Drug Discov*. 2020;19(7):463–479. doi:10.1038/s41573-020-0064-x
45. Liu LP, Zheng YW. Predicting differentiation potential of human pluripotent stem cells: possibilities and challenges. *World J Stem Cells*. 2019 Jul 26;11(7):375–382. doi:https://dx.doi.org/10.4252/wjsc.v11.i7.375
46. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics—recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. *Clin Pharmacol Ther*. 2007 Sep;82(3):252–264. doi:10.1038/sj.clpt.6100301
47. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. *Int J Biochem Cell Biol*. 2004 Apr;36(4):568–584. doi:10.1016/j.biocel.2003.11.001
48. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science*. 2014 Jul 18;345(6194):1247125. doi:10.1126/science.1247125

49. Li M, Izpisua Belmonte JC. Organoids - Preclinical Models of Human Disease. *N Engl J Med*. 2019 Feb 7;380(6):569-579. doi:10.1056/NEJMra1806175
50. Smernoff N. Mesenchymal Stromal Cells and Their Uses in Bio-Regenerative Therapies for Bone and Cartilage: A Review. *J Regener Med*. 2024 Mar;13(1). doi:10.4236/ojrm.2024.131001
51. Hussien BM, Taheri M, Yashoo RK, Abdullah GH, Abdullah SR, Kheder RK, Mustafa SA. Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. *Int J SSurg*. 2024 Dec 1;110(12):8002–8024. doi: 10.1097/JS9.0000000000002109
52. Fani N, Moradi M, Zavari R, Parvizpour F, Soltani A, Arabpour Z, Jafarian A. Current advances in wound healing and regenerative medicine. *Curr Stem Cell Res Ther*. 2024;19(3):277–291. doi: 10.2174/1574888X18666230301140659
53. Morizane R, Lamers MM. Organoids in disease modeling and regenerative medicine. *Cell Mol Life Sci*. 2025;82(1):169. doi: 10.1007/s00018-025-05692-y
54. Khodve G, Banerjee S, Kumari M, Ravichandiran V, Banerjee S, Roy S. Exploration of biomaterial and stem cell-based strategies for promoting neuronal regeneration and creating engineered 3D in vitro disease models. *J Transl Med*. 2025;23:1197. Doi: <https://doi.org/10.1186/s12967-025-07266-9>
55. Lamichhane TN, Sokic S, Schardt JS, Raiker RS, Lin JW, Jay SM. Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. *Tissue Eng Part B Rev*. 2015;21(1):45–54. doi: 10.1089/ten.teb.2014.0300
56. Loukelis K, Koutsomarkos N, Mikos AG, Chatzinikolaidou M. Advances in 3D bioprinting for regenerative medicine applications. *Regen Biomater*. 2024;11:rbae033. doi: 10.1093/rb/rbae033
57. Zhang D, Yin H, Wu C, Li S, Nabi G, Peng L, Mao X, Jin Z, Li Z, Su X, Huang H. Targeting regulatory T-cells in pancreas during acute pancreatitis: Programmed-death 1 blockage as a potential therapeutic for infectious pancreatic necrosis. *Clin Transl Med*. 2023;13:1472. doi:<https://doi.org/10.1002/ctm2.1472>
58. Chengebroyen N, Seelan A, Thajudeen KY, Alshehri SA, Biswas A, Adur I, Sundararajan V, Sudhakaran SL, Singh H. Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments – a state-of-the-art update. *Front Pharmacol*. 2025;16:1630475. doi: 10.3389/fphar.2025.1630475
59. Patel SA, King CC, Lim PK, Habiba U, Dave M, Porecha R, Rameshwar P. Personalizing stem cell research and therapy: the arduous road ahead or missed opportunity? *Curr Pharmacogenomics Person Med*. 2010;8(1):1–12. doi:10.2174/1875692111008010025
60. Chen X, Guo Z, Tong X, Wang X, Liu X, Nagai H, et al. Derivation of embryonic stem cells across avian species. *Nat Biotechnol*. 2025; doi:<https://doi.org/10.1038/s41587-025-02833-3>.
61. Cable J, Fuchs E, Weissman I, Jasper H, Glass D, Rando T, et al. Adult stem cells and regenerative medicine—a symposium report. *Ann N Y Acad Sci*. 2020;1462(1):27–36. doi:10.1111/nyas.14243.
62. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. *Stem Cells*. 2009 May;27(5):1050–1056. doi:<https://doi.org/10.1002/stem.37>.
63. Wang Z. Assessing tumorigenicity in stem cell-derived therapeutic products: a critical step in safeguarding regenerative medicine. *Bioengineering (Basel)*. 2023 Jul 19;10(7):857. doi:<https://doi.org/10.3390/bioengineering10070857>.
64. Tan, F., Li, X., Wang, Z. et al. Clinical applications of stem cell-derived exosomes. *Signal Transduct Target Ther* 9, 17 (2024). doi: <https://doi.org/10.1038/s41392-023-01704-0>.
65. Copelan EA. Hematopoietic stem-cell transplantation. *N Engl J Med*. 2006;354(17):1813–26. <https://doi.org/10.1056/NEJMra052638>.
66. Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. *Nat Rev Mol Cell Biol*. 2016;17(3):194–200. <https://doi.org/10.1038/nrm.2016.10>.
67. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. *Cell Stem Cell*. 2018;22(6):824–33. <https://doi.org/10.1016/j.stem.2018.05.004>.
68. Driscoll J, Kurtz A. Stem cell therapy: translational challenges. *Nat Rev Drug Discov*. 2009;8(9):717–24. <https://doi.org/10.1038/nrd2978>.

69. Han X, Liao R, Li X, Zhang C, Huo S, Qin L, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. *Signal Transduct Target Ther.* 2025;10:262. doi:<https://doi.org/10.1038/s41392-025-02313-9>.
70. Sekaran, Shamala Devi*; Manikam, Rishya1; Thergerajan, Gaythri2; Prasad, Haymond3; Alagar, Munandy3; Tan, Chung Keat4. The role of personalized precision medicine in enhancing diagnostic accuracy and clinical outcomes. *Advances in Biomedical and Health Sciences* 4(2):p 52-60, Apr–Jun 2025. | doi: https://doi.org/10.4103/abhs.abhs_105_24.
71. Ding S. Therapeutic reprogramming toward regenerative medicine. *Chem Rev.* 2025;125(4):1805–1822. doi:<https://doi.org/10.1021/acs.chemrev.4c00332>.
72. Inoue, H., Nagata, N., Kurokawa, H., & Yamanaka, S. (2014). iPS cells: a game changer for future medicine. *The EMBO Journal*, 33, 409 - 417. <https://doi.org/10.1002/emboj.201387098>.
73. Mohite, P., Puri, A., Dave, R., Budar, A., Munde, S., Ghosh, S., Alqahtani, T., Shmrany, H., Kumer, A., & Dhara, B. (2024). Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies. *International Journal of Surgery (London, England)*, 110, 6432 - 6455. <https://doi.org/10.1097/js9.0000000000001892>.
74. Musunuru, K., Sheikh, F., Gupta, R., Houser, S., Maher, K., Milan, D., Terzic, A., & Wu, J. (2018). Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.. *Circulation: Genomic and Precision Medicine*. <https://doi.org/10.1161/hcg.0000000000000043>.
75. Aboul-Soud MA, Alzahrani A, Mahmoud A. Induced pluripotent stem cells (iPSCs): roles in regenerative therapies, disease modelling and drug screening. *Cells.* 2021;10(4):919. <https://doi.org/10.3390/cells10040919>.
76. Wang, Z., Zheng, J., Pan, R., & Chen, Y. (2021). Current status and future prospects of patient-derived induced pluripotent stem cells. *Human Cell*, 34, 1601 - 1616. <https://doi.org/10.1007/s13577-021-00592-2>.
77. Madrid, M., Sumen, C., Aivio, S., & Saklayen, N. (2021). Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges. *Current Protocols*, 1. <https://doi.org/10.1002/cpz1.88>.
78. Rowe, R., & Daley, G. (2019). Induced pluripotent stem cells in disease modelling and drug discovery. *Nature Reviews Genetics*, 20, 377 - 388. <https://doi.org/10.1038/s41576-019-0100-z>.
79. Silva, M., & Haggarty, S. (2019). Human pluripotent stem cell–derived models and drug screening in CNS precision medicine. *Annals of the New York Academy of Sciences*, 1471. <https://doi.org/10.1111/nyas.14012>.
80. Yang Y, et al. A live-cell image-based machine learning strategy for reducing variability in PSC differentiation systems. *Cell Discov.* 2023;9:43. <https://doi.org/10.1038/s41421-023-00543-1>.
81. Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and β -thalassemia. *N Engl J Med.* 2021;384(3):252 60. <https://doi.org/10.1056/NEJMoa2031054>.
82. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. *Nat Cell Biol.* 2016;18(3):246–54. <https://doi.org/10.1038/ncb3312>.
83. Takebe T, Wells JM. Organoids by design. *Science.* 2019;364(6444):956–9. <https://doi.org/10.1126/science.aaw7567>.
84. Shafiee A, Atala A. Printing technologies for medical applications. *Trends Mol Med.* 2016;22(3):254 65. <https://doi.org/10.1016/j.molmed.2016.01.003>.
85. Dong, Y., Wu, X., Chen, X., Zhou, P., Xu, F., & Liang, W. (2021). Nanotechnology shaping stem cell therapy: Recent advances, application, challenges, and future outlook. *Biomedicine & Pharmacotherapy*, 137, 111236. <https://doi.org/10.1016/j.biopha.2021.111236>.
86. Thamarai, P., Karishma, S., Kamalesh, R., Shaji, A., Saravanan, A., Bibi, S., Vickram, A. S., Chopra, H., Saleem, R. A., Alsharif, K. F., Theyab, A., Kamel, M., Alamoudi, M. K., Kumer, A., Chopra, S., & Abdel-Daim, M. M. (2024). Current advancements in nanotechnology for stem cells. *International Journal of Surgery*, 110(12), 7456–7476. <https://doi.org/10.1097/js9.0000000000002082>.
87. Bolton, E. M., & Bradley, J. A. (2015). Avoiding Immunological Rejection in Regenerative Medicine. *Regenerative Medicine*, 10(3), 287–304. <https://doi.org/10.2217/rme.15.11>.

88. Wood, K. J., Issa, F., & Hester, J. (2016). Understanding Stem Cell Immunogenicity in Therapeutic Applications. *Trends in Immunology*, 37(1), 5–16. <https://doi.org/10.1016/j.it.2015.11.005>
89. Jayaram, P., Danilkowicz, R. M., & Yuan, X. (2025). Ethical and Regulatory Considerations Related to Regenerative Medicine. *HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery*, 21(4), 463–468. <https://doi.org/10.1177/15563316251361511>
90. Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018). Ethical and Safety Issues of Stem Cell-Based Therapy. *International Journal of Medical Sciences*, 15(1), 36–45. <https://doi.org/10.7150/ijms.21666>
91. Hunsberger, J., & Somara, S. (2022). Manufacturing challenges and solutions for regenerative medicine technologies. In *Regenerative Nephrology* (pp. 487–500). Elsevier. <https://doi.org/10.1016/b978-0-12-823318-4.00014-7>
92. Selfa Aspiroz, L., Mennecozzi, M., Batlle, L., Corneo, B., Healy, L., Kotter, M., Kurtz, A., Ludwig, T. E., Mummery, C., Pera, M., Stacey, G. N., Tristan, C. A., & Whelan, M. (2025). Promoting the adoption of best practices and standards to enhance quality and reproducibility of stem cell research. *Stem Cell Reports*, 20(7), 102531. <https://doi.org/10.1016/j.stemcr.2025.102531>
93. Ahmed SA, Saikia A, Devi SG, Borah JC. AI-assisted cell culture system. *Methods Mol Biol*. 2025;2952:149–167. doi:10.1007/978-1-0716-4690-8_9.
94. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. *Comput Struct Biotechnol J*. 2015;13:8–17. <https://doi.org/10.1016/j.csbj.2014.11.005>
95. Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. *Nat Rev Genet*. 2015;16(6):321–32. <https://doi.org/10.1038/nrg3920>
96. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346(6213):1258096. <https://doi.org/10.1126/science.1258096>
97. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell*. 2014;157(6):1262–78. <https://doi.org/10.1016/j.cell.2014.05.010>
98. Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. *Curr Opin Biotechnol*. 2021;66:112–20. <https://doi.org/10.1016/j.cotox.2021.08.006>
99. Tang, X.-Y., Wu, S., Wang, D., Chu, C., Hong, Y., Tao, M., Hu, H., Xu, M., Guo, X., & Liu, Y. (2022). Human organoids in basic research and clinical applications. *Signal Transduction and Targeted Therapy*, 7(1). <https://doi.org/10.1038/s41392-022-01024-9>
100. Fetah, K., Tebon, P., Goudie, M. J., Eichenbaum, J., Ren, L., Barros, N., Nasiri, R., Ahadian, S., Ashammakhi, N., Dokmeci, M. R., & Khademhosseini, A. (2019). The emergence of 3D bioprinting in organ-on-chip systems. *Progress in Biomedical Engineering*, 1(1), 012001. <https://doi.org/10.1088/2516-1091/ab23df>
101. Vanaei, S., Parizi, M. S., Vanaei, S., Saleemizadehparizi, F., & Vanaei, H. R. (2021). An Overview on Materials and Techniques in 3D Bioprinting Toward Biomedical Application. *Engineered Regeneration*, 2, 1–18. <https://doi.org/10.1016/j.engreg.2020.12.001>
102. Tandon, N., Cimetta, E., Bhumiratana, S., Godier-Furnemont, A., Maidhof, R., & Vunjak-Novakovic, G. (2013). Bioreactors for Tissue Engineering. In *Biomaterials Science* (pp. 1178–1194). Elsevier. <https://doi.org/10.1016/b978-0-08-087780-8.00112-1>
103. Zhang, H., & Wang, Z. Z. (2008). Mechanisms that mediate stem cell self-renewal and differentiation. *Journal of cellular biochemistry*, 103(3), 709–718. <https://doi.org/10.1002/jcb.21460>
104. Seita, J., & Weissman, I. L. (2010). Hematopoietic stem cell: self-renewal versus differentiation. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 2(6), 640–653. <https://doi.org/10.1002/wsbm.86>
105. Mitalipov, S., & Wolf, D. (2009). Totipotency, pluripotency and nuclear reprogramming. *Engineering of stem cells*, 185–199. https://doi.org/10.1007/10_2008_45
106. Jaenisch, R., & Young, R. (2008). Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell*, 132(4), 567–582. <https://doi.org/10.1016/j.cell.2008.01.015>

107. Hicks, M. R., & Pyle, A. D. (2023). The emergence of the stem cell niche. *Trends in cell biology*, 33(2), 112-123. <https://doi.org/10.1016/j.tcb.2022.07.003>
108. Scadden, D. T. (2014). Nice neighborhood: emerging concepts of the stem cell niche. *Cell*, 157(1), 41-50. <http://dx.doi.org/10.1016/j.cell.2014.02.013>
-



© 2026 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by-nc-sa/4.0/>).